Biomx Ltd (PHGE) Stock Price, Quote & News

Company Profile

BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from...

Industry: Biotechnology

Sector: Healthcare

Website: www.biomx.com

Address:

850 New Burton Road, Suite 201, Dover, United States

Royal_Imperial Apr. 24 at 9:36 PM

MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $PHGE $LXEH $HUBC $RAYA /.55

0 · Reply

forsiz1 Apr. 24 at 5:31 PM

$PHGE What happened to Solomon's phage therapy work? Will anyone buy the patents and take over the trials?

0 · Reply

forsiz1 Apr. 24 at 5:29 PM

$PHGE When are we moving back up? Added more today 👍

0 · Reply

DragonOfBosnia Apr. 24 at 3:30 PM

$PHGE from $5———-$1 in a month…

1 · Reply

DragonOfBosnia Apr. 24 at 3:22 PM

$AMZE $DFNS $PHGE

0 · Reply

forsiz1 Apr. 24 at 5:42 AM

$PHGE Definitely oversold at current level. Adding more tomorrow if it doesn't pop tomorrow 👍

0 · Reply

NotYahoo_ Apr. 24 at 12:32 AM

$PHGE so we have untiltomorrow for the 🚀 , obviously 50%^up

0 · Reply

ASseenONtv Apr. 23 at 11:25 PM

$PHGE Need more rope for this anchor.

0 · Reply

forsiz1 Apr. 23 at 8:53 PM

$PHGE Major drone contract coming ? 👍

0 · Reply

forsiz1 Apr. 23 at 8:35 PM

$PHGE $5 soon

0 · Reply

Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems

Apr 13, 2026, 9:20 AM EDT - 12 days ago

BiomX Accelerates Defense Technology Buildout with DFSL Acquisition

Apr 10, 2026, 8:30 AM EDT - 15 days ago

BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications

Mar 31, 2026, 10:48 AM EDT - 25 days ago

BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System

Mar 30, 2026, 9:28 AM EDT - 26 days ago

BiomX Adds Former Mossad Deputy to Advisory Board

Mar 27, 2026, 4:30 PM EDT - 4 weeks ago

BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

Mar 26, 2026, 8:48 AM EDT - 4 weeks ago

BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations

Mar 19, 2026, 9:15 AM EDT - 5 weeks ago

BiomX CEO Issues Letter to Stockholders

Mar 11, 2026, 8:00 AM EDT - 6 weeks ago

BiomX Transcript: EGM 2026

Mar 9, 2026, 9:00 AM EDT - 6 weeks ago

BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

Feb 25, 2026, 8:00 AM EST - 2 months ago

BiomX Transcript: EGM 2026

Jan 27, 2026, 1:41 PM EST - 3 months ago

BiomX Issues Statement Regarding Recent Common Stock Trading Activity

Dec 29, 2025, 8:00 AM EST - 4 months ago

BiomX Announces $3.0 Million Private Placement

Nov 26, 2025, 1:23 PM EST - 5 months ago

BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review

Nov 25, 2025, 4:40 PM EST - 5 months ago

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

Nov 12, 2025, 8:30 AM EST - 5 months ago

BiomX Earnings Call Transcript: Q3 2025

Nov 12, 2025, 7:30 AM EST - 5 months ago

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

Oct 17, 2025, 8:30 AM EDT - 6 months ago

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

Aug 19, 2025, 8:19 AM EDT - 8 months ago

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

Aug 13, 2025, 8:00 AM EDT - 9 months ago

BiomX Earnings Call Transcript: Q2 2025

Aug 13, 2025, 6:30 AM EDT - 9 months ago

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

Aug 6, 2025, 8:30 AM EDT - 9 months ago

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

Jul 14, 2025, 9:00 AM EDT - 10 months ago

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

Jul 8, 2025, 8:30 AM EDT - 10 months ago

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

May 19, 2025, 10:02 AM EDT - 1 year ago

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 15, 2025, 2:00 PM EDT - 1 year ago

BiomX Earnings Call Transcript: Q1 2025

May 15, 2025, 6:30 AM EDT - 1 year ago

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 8, 2025, 7:00 AM EDT - 1 year ago

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

Apr 3, 2025, 11:00 AM EDT - 1 year ago

BiomX Transcript: KOL Event

Apr 1, 2025, 6:30 AM EDT - 1 year ago

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025, 9:00 AM EDT - 1 year ago

BiomX Earnings Call Transcript: Q4 2024

Mar 31, 2025, 6:30 AM EDT - 1 year ago

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Mar 25, 2025, 6:30 AM EDT - 1 year ago

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

Mar 19, 2025, 12:35 PM EDT - 1 year ago

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Nov 14, 2024, 8:00 AM EST - 1 year ago

BiomX Earnings Call Transcript: Q3 2024

Nov 14, 2024, 6:30 AM EST - 1 year ago

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Nov 12, 2024, 12:20 PM EST - 1 year ago

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BiomX Announces a Mandatory Unit Separation

Sep 18, 2024, 8:00 AM EDT - 1 year ago

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

BiomX Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 4, 2024, 8:00 AM EDT - 1 year ago

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 10:55 AM EDT - 1 year ago

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 8:00 AM EDT - 1 year ago

BiomX Earnings Call Transcript: Q2 2024

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Explode In Q3

DXCM EW

Jul 29, 2024, 7:00 AM EDT - 1 year ago

BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Jul 10, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

May 30, 2024, 4:50 PM EDT - 2 years ago

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

May 30, 2024, 7:00 AM EDT - 2 years ago

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

May 21, 2024, 8:00 AM EDT - 2 years ago

BiomX Earnings Call Transcript: Q1 2024

May 21, 2024, 6:30 AM EDT - 2 years ago

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

May 15, 2024, 7:00 AM EDT - 2 years ago

BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

Apr 23, 2024, 8:00 AM EDT - 2 years ago

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Apr 18, 2024, 8:00 AM EDT - 2 years ago

BiomX Announces the Appointment of Susan Blum to its Board of Directors

Apr 3, 2024, 8:00 AM EDT - 2 years ago

BiomX Earnings Call Transcript: Q4 2023

Apr 3, 2024, 6:30 AM EDT - 2 years ago

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 27, 2024, 6:30 AM EDT - 2 years ago

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

Mar 18, 2024, 6:30 AM EDT - 2 years ago

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Mar 6, 2024, 7:30 AM EST - 2 years ago

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Aug 9, 2023, 8:00 AM EDT - 2 years ago

BiomX Earnings Call Transcript: Q2 2023

May 15, 2023, 8:00 AM EDT - 3 years ago

BiomX Earnings Call Transcript: Q1 2023

Mar 29, 2023, 8:00 AM EDT - 3 years ago

BiomX Earnings Call Transcript: Q4 2022

Royal_Imperial Apr. 24 at 9:36 PM

0 · Reply

forsiz1 Apr. 24 at 5:31 PM

$PHGE What happened to Solomon's phage therapy work? Will anyone buy the patents and take over the trials?

0 · Reply

forsiz1 Apr. 24 at 5:29 PM

$PHGE When are we moving back up? Added more today 👍

0 · Reply

DragonOfBosnia Apr. 24 at 3:30 PM

$PHGE from $5———-$1 in a month…

1 · Reply

DragonOfBosnia Apr. 24 at 3:22 PM

$AMZE $DFNS $PHGE

0 · Reply

forsiz1 Apr. 24 at 5:42 AM

$PHGE Definitely oversold at current level. Adding more tomorrow if it doesn't pop tomorrow 👍

0 · Reply

NotYahoo_ Apr. 24 at 12:32 AM

$PHGE so we have untiltomorrow for the 🚀 , obviously 50%^up

0 · Reply

ASseenONtv Apr. 23 at 11:25 PM

$PHGE Need more rope for this anchor.

0 · Reply

forsiz1 Apr. 23 at 8:53 PM

$PHGE Major drone contract coming ? 👍

0 · Reply

forsiz1 Apr. 23 at 8:35 PM

$PHGE $5 soon

0 · Reply

Moon1987 Apr. 23 at 6:54 PM

$DFNS $PHGE $AMZE 100% Neil Bhatia and Toffer Nelson, both pumped all of these tickers at the highest point, now look where they are. Any stock the try to promote, please be EXTREMELY careful everyone 🙏🙏

0 · Reply

DragonOfBosnia Apr. 23 at 4:19 PM

$AMZE $DFNS $PHGE

0 · Reply

forsiz1 Apr. 23 at 3:07 PM

$PHGE Waiting for the MOASS move soon 👍 $7.X this time?

0 · Reply

NotYahoo_ Apr. 23 at 12:46 PM

$PHGE let's Go!

1 · Reply

toffernelson Apr. 21 at 6:26 PM

$PHGE

1 · Reply

forsiz1 Apr. 21 at 4:37 PM

$PHGE Who is still holding ?

1 · Reply

NotYahoo_ Apr. 21 at 10:17 AM

$PHGE are they gonna jump into 🍄business or what? ...wouldn't mind

0 · Reply

ASseenONtv Apr. 20 at 11:35 PM

$PHGE I think the casino has been more predictable lately.

0 · Reply

NotYahoo_ Apr. 20 at 10:56 PM

$PHGE every you !

0 · Reply

RichMitch Apr. 20 at 9:27 PM

$AMS $MYSE $BZAI $PHGE $LSTA Hmmm 🤔

0 · Reply

Goethe14 Apr. 20 at 7:55 PM

$PHGE congrats on the new 52 week low.

0 · Reply

rich54 Apr. 20 at 5:25 PM

$PHGE lot of mkt/stock manipulation starts from Israel. They know SEC rules inside out. Lot of hired goons like Epstein, Neil Bhatia seem to be on their payroll as well. Neil has gotten in trouble with law enforcement before and I wonder who helped him sort things out…

1 · Reply

Market Cap	1.91M
Revenue (ttm)	0.00
Net Income (ttm)	-36.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	265,400
Avg Vol	142,134
Day's Range	N/A - N/A
Shares Out	1.59M
Stochastic %K	3%
Beta	1.69
Analysts	Hold
Price Target	$26.00